# Heart Failure with Reduced Ejection Fraction (HFrEF) — EF ≤40%

## Guideline-Directed Medical Therapy (GDMT) — Four Pillars
All four drug classes should be initiated and titrated to target doses:

### 1. RAAS Inhibition
- **ACEi**: Enalapril 10-20mg BID, Lisinopril 20-40mg daily, Ramipril 10mg daily
- **ARB** (if ACEi intolerant): Valsartan 160mg BID, Losartan 150mg daily
- **ARNI** (preferred over ACEi/ARB): Sacubitril/valsartan 97/103mg BID — requires 36hr washout from ACEi

### 2. Beta-Blockers
- **Carvedilol** 25mg BID (50mg BID if >85kg), **Metoprolol succinate** 200mg daily, **Bisoprolol** 10mg daily
- Start low, titrate every 2 weeks; do not initiate during acute decompensation

### 3. Mineralocorticoid Receptor Antagonists (MRA)
- **Spironolactone** 25-50mg daily or **Eplerenone** 50mg daily
- Contraindicated if K+ >5.0 or eGFR <30; monitor potassium closely

### 4. SGLT2 Inhibitors
- **Dapagliflozin** 10mg daily or **Empagliflozin** 10mg daily
- Benefit regardless of diabetes status; can initiate early

## Additional Therapies
- **Hydralazine/isosorbide dinitrate**: For Black patients or if ACEi/ARB/ARNI intolerant
- **Ivabradine**: If sinus rhythm with HR ≥70 despite maximized beta-blocker
- **Diuretics**: Loop diuretics (furosemide, bumetanide, torsemide) for volume overload — titrate to euvolemia
- **Digoxin**: May reduce HF hospitalizations; target level 0.5-0.9 ng/mL

## Device Therapy
- **ICD**: Primary prevention if EF ≤35% despite ≥3 months GDMT, NYHA II-III, expected survival >1 year
- **CRT**: If EF ≤35%, LBBB with QRS ≥150ms, NYHA II-IV despite GDMT

## Monitoring
- Daily weights, sodium restriction (<2g/day), fluid restriction if severe hyponatremia
- Labs: BMP (K+, creatinine) 1-2 weeks after RAAS/MRA changes
- Warning signs: Weight gain >3 lbs in 1 day or >5 lbs in 1 week

## Avoid
- NSAIDs, non-dihydropyridine CCBs (verapamil, diltiazem), thiazolidinediones, most antiarrhythmics except amiodarone/dofetilide
